MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.288
AS - Asia 6.407
EU - Europa 4.585
SA - Sud America 965
Continente sconosciuto - Info sul continente non disponibili 228
AF - Africa 106
OC - Oceania 33
Totale 25.612
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.929
SG - Singapore 2.124
CN - Cina 1.646
IT - Italia 1.187
GB - Regno Unito 963
BR - Brasile 732
HK - Hong Kong 718
VN - Vietnam 641
FI - Finlandia 489
DE - Germania 405
SE - Svezia 392
BD - Bangladesh 389
RU - Federazione Russa 247
FR - Francia 239
KR - Corea 197
CA - Canada 165
UA - Ucraina 149
TR - Turchia 138
NL - Olanda 104
IN - India 95
BG - Bulgaria 89
ID - Indonesia 87
AR - Argentina 86
JP - Giappone 77
MX - Messico 60
AT - Austria 56
IQ - Iraq 54
ES - Italia 39
AE - Emirati Arabi Uniti 36
PL - Polonia 36
EC - Ecuador 35
IE - Irlanda 31
AU - Australia 30
ZA - Sudafrica 30
PK - Pakistan 29
CL - Cile 27
CO - Colombia 27
CR - Costa Rica 27
LT - Lituania 25
MA - Marocco 23
VE - Venezuela 23
BZ - Belize 20
BE - Belgio 18
CH - Svizzera 18
UZ - Uzbekistan 18
PH - Filippine 17
TH - Thailandia 17
KW - Kuwait 14
MY - Malesia 14
PT - Portogallo 14
CZ - Repubblica Ceca 13
JM - Giamaica 13
NP - Nepal 13
PE - Perù 13
TW - Taiwan 13
HU - Ungheria 12
GR - Grecia 11
GT - Guatemala 11
SA - Arabia Saudita 11
DO - Repubblica Dominicana 10
DZ - Algeria 10
KE - Kenya 10
AZ - Azerbaigian 9
PR - Porto Rico 9
KG - Kirghizistan 8
NI - Nicaragua 8
PY - Paraguay 8
TT - Trinidad e Tobago 8
EG - Egitto 7
UY - Uruguay 7
AL - Albania 6
EE - Estonia 6
IL - Israele 6
JO - Giordania 6
RO - Romania 6
SV - El Salvador 6
TN - Tunisia 6
DK - Danimarca 5
EU - Europa 5
LV - Lettonia 5
HN - Honduras 4
IR - Iran 4
SN - Senegal 4
AG - Antigua e Barbuda 3
BO - Bolivia 3
BS - Bahamas 3
BY - Bielorussia 3
CU - Cuba 3
CW - ???statistics.table.value.countryCode.CW??? 3
GY - Guiana 3
KH - Cambogia 3
KY - Cayman, isole 3
LB - Libano 3
MT - Malta 3
NZ - Nuova Zelanda 3
OM - Oman 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
Totale 25.347
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.574
Ashburn 1.551
Singapore 1.273
Fairfield 1.026
San Jose 784
Hong Kong 709
Hefei 586
Woodbridge 575
Houston 478
Council Bluffs 472
Southend 461
Seattle 448
Chandler 438
Helsinki 433
Wilmington 327
Cambridge 306
London 296
Beijing 271
New York 266
Ann Arbor 255
Nyköping 235
Ho Chi Minh City 227
Jacksonville 213
The Dalles 211
Los Angeles 204
Dearborn 193
Seoul 193
Modena 181
Munich 149
Milan 143
Hanoi 137
Dallas 124
Chicago 121
Lauterbourg 113
San Diego 113
Moscow 98
Buffalo 94
Princeton 78
Sofia 78
São Paulo 73
Columbus 70
Boardman 66
Shanghai 64
Eugene 54
Jakarta 54
Rome 50
Bologna 48
Tokyo 46
Nuremberg 44
Salt Lake City 42
North Bergen 41
Amsterdam 37
Izmir 37
Phoenix 37
Redondo Beach 37
Orem 36
Rio de Janeiro 35
Kent 34
Atlanta 32
Brooklyn 32
Saint Augustine 32
Frankfurt am Main 30
Haiphong 30
Toronto 30
Dublin 29
Redwood City 29
Denver 26
Florence 25
Montreal 25
Naples 25
Washington 25
Da Nang 24
Elk Grove Village 24
Mexico City 23
Reggio Emilia 23
Guangzhou 22
Brasília 21
Belize City 20
Vienna 20
Johannesburg 19
Lappeenranta 19
Boston 18
San José 18
Brussels 17
Chennai 17
Palermo 17
Warsaw 17
Baghdad 16
Las Vegas 16
Miano 16
Parma 16
Philadelphia 16
Portsmouth 16
San Francisco 16
Tashkent 16
Waltham 16
Ankara 15
Kilburn 15
Mumbai 15
Quito 15
Totale 17.232
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 400
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 360
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 360
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 333
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 333
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 328
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 309
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 309
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 306
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 303
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 302
Biotherapies in large vessel vasculitis 296
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 295
Imaging of vasculitis: State of the art 291
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 290
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 288
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 288
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 283
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 280
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 278
Updates on the diagnosis and monitoring of giant cell arteritis 277
Biologics in vasculitides: Where do we stand, where do we go from now? 272
Increased expression of interleukin-22 in patients with giant cell arteritis 271
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 269
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 266
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 264
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 261
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 258
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 253
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 252
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 250
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 248
Tocilizumab for the treatment of giant cell arteritis 246
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 245
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 242
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 242
Large-vessel giant cell arteritis: a cohort study 239
Statin use in giant cell arteritis: a retrospective study 239
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 239
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 237
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 237
Mycophenolate mofetil in primary central nervous system vasculitis 234
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 232
Giant Cell Arteritis and Polymyalgia Rheumatica 231
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 231
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 231
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 221
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 220
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 218
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 217
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 216
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 216
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 216
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 214
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 212
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 212
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 207
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 206
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 206
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 200
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 200
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 200
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 197
L30. Assessment of vasculitis extent and severity 195
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 194
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 191
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 191
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 191
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 189
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 187
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 187
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 186
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 182
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 178
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 178
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 178
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 178
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 178
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 177
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 177
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 177
Development of the Takayasu Arteritis Integrated Disease Activity Index 176
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 176
What to Know About Biopsy Sampling and Pathology in Vasculitis? 175
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 170
Eosinophilic giant cell arteritis: A different subset of disease? 165
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 164
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 163
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 161
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 160
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 160
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 156
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 156
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 155
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 155
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 152
Role of miR-146a and miR-146b in Giant Cell Arteritis. 151
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 151
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 150
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 150
Totale 22.636
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.114 0 0 0 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20269.044 652 414 774 873 960 612 1.203 451 955 684 798 668
2026/20272.585 378 627 646 934 0 0 0 0 0 0 0 0
Totale 25.612